Previous 10 |
LOS ANGELES , Oct. 16, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that pursuant to an Order of the Superior Court of California, County of Los Angeles , entered on October 3, 2019 , in the matter of David Wiener , derivatively...
LOS ANGELES , Aug. 28, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC) today announced receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular's remaining assets, inc...
LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today issued the following announcement. The following is being released pursuant to an Order of the Superior Court of California, County of Los Angeles, entered...
LOS ANGELES , July 16, 2019 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced an agreement with a privately held biotechnology company (the "Purchaser") for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-cli...
In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
ImmunoCellular Therapeutics Ltd. Company Name:
IMUC Stock Symbol:
OTCMKTS Market:
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613 PR Newswire MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug...
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil PR Newswire Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , ...
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology indu...